Back to results
US 11,229,664 B2Granted
Treatment of myelosuppression
AssigneeCantex Pharmaceuticals, Inc.
InventorStephen Marcus
Life of this patent
Estimating the term…
Abstract
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
Claims20
In a method of administering a chemotherapeutic agent to a subject with acute myeloid leukemia (AML), wherein the chemotherapeutic agent is a pyrimidine antagonist, an anthracycline agent, or a combination thereof, the improvement comprising:
- adjunctively administering to the subject a heparinoid that is substantially desulfated at the 2-O and 3-O positions, in an amount that is effective to attenuate a myelosuppressive side effect of the chemotherapeutic agent.
A method of treating acute myeloid leukemia (AML), comprising:
- administering to a subject with AML, a pyrimidine antagonist, an anthracycline agent, and a heparinoid substantially desulfated at the 2-O and 3-O positions, comprising:
- administering the pyrimidine antagonist as a continuous intravenous infusion for Days 1 through 7 of at least one 28-day cycle;
- administering the anthracycline agent as an intravenous injection or an intravenous infusion once daily for Days 1 through 3 of the at least one 28-day cycle;
- and
- administering the heparinoid as a bolus injection at a dose of 4 mg/kg on Day 1 followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hr for Days 1 through 7 of the at least one 28-day cycle.
2 more elements
Dependencies are inferred from the claim text.